News Type: Press Release

Aceragen announces dosing of first patient with ACG-701 in clinical trial for treatment of melioidosis

$45 million clinical program funded by the Defense Threat Reduction Agency- Trial initiates clinical development effort in support of ACG-701 as a treatment for multiple life-threatening orphan pulmonary diseases, including cystic fibrosis RALEIGH-DURHAM, NC – June 15, 2022 – Aceragen, Inc., a clinical-stage biopharmaceutical company developing therapies for rare pulmonary and rheumatic diseases with high unmet

Aceragen Announces $3.5 Million Development Award from Cystic Fibrosis Foundation to Progress Novel Therapy for CF-Related Exacerbations

Agreement supports late-stage clinical study for ACG-701 beginning in 2022 Advances Aceragen’s development effort to treat life-threatening rare and orphan diseases RALEIGH-DURHAM, NC – January 06, 2022 – Aceragen, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics for orphan diseases with high unmet medical need, today announced that its wholly-owned subsidiary, Arrevus, Inc., has received

Aceragen’s wholly-owned subsidiary, Arrevus, awarded $45 million funding agreement from the Department of Defense’s Defense Threat Reduction Agency for Development of ACG-701 as Medical Countermeasure Against Melioidosis

Agreement supports development, manufacturing, and Phase 2 clinical development Program provides significant value to Aceragen’s overall development of ACG-701 for the treatment of life-threatening orphan infectious diseases RALEIGH-DURHAM, NC – January 05, 2022 – Arrevus, Inc., a clinical-stage biopharmaceutical company developing therapies for orphan infectious diseases with high unmet medical need, today announced it has

Aceragen Announces Acquisition of Arrevus, Expands Late-Stage Rare Disease Pipeline

Combination advances strategy of building multi-product commercial rare disease company Portfolio to address Farber disease, Cystic Fibrosis, and Orphan Infectious Diseases RALEIGH-DURHAM, NC – October 28, 2021 – Aceragen, Inc., a biopharmaceutical company focused on advancing transformational therapeutics for rare and orphan diseases, today announced the acquisition of Arrevus, Inc., a clinical-stage biopharmaceutical company developing

Focused On Rare Illnesses, North Carolina Startup Aceragen Goes After Farber Disease

A new North Carolina-based biopharmaceutical company with a focus on rare illnesses hopes to be the first to find a treatment for Farber disease. This extremely rare genetic disorder results in the buildup of a material in the body called ceramide that can inflame and damage many different tissues. Joints, connective tissue, the lungs and

Aceragen Launches with Acquisition of Enzyvant’s Investigational Therapy for Farber Disease and $35 Million Product Financing with NovaQuest

Acquires worldwide rights to RVT-801, a novel enzyme replacement therapy for treatment of Farber disease NovaQuest investment to fund product and clinical development Protocol for potential single registration study reviewed with FDA and EMA Program has been granted rare pediatric disease status, fast track and orphan designations, and is eligible for a priority review voucher